Helicobacter pylori eradication treatment for primary gastric diffuse large B-cell lymphoma: A single-center analysis

Table 1 Clinical characteristics of 6 cases

Case	Age	Sex	Number of lesions	Endoscopic morphology	MALT lymphoma component	Comorbidities	Therapeutic effect	Additional treatment	Current condition	Ref.
1	71	Male	1	Ulcerative	(-)	Diabetes	CR	(-)	Maintaining CR (≥ 6 yr)
2	67	Female	1	Superficial	(+)	IgG4-related disease	CR	(-)	Maintaining CR (≥ 6 yr)
3	90	Male	2	Ulcerative. Elevated	(-)	MGUS	CR. SD	RTX (1/wk) × 4 wk	Alive with disease (2 yr)
A	27	Female	1	Ulcerative	(-)	(-)	CR	R-CHOP × 3 courses + gastric irradiation	Maintaining CR (≥ 9 yr)	[8]
B	70	Male	2	Ulcerative (both 2 lesions)	(-)	Diabetes	CR (both lesions). Recurrence (PD)	R-THP-COP × 6 courses	Maintaining CR (≥ 6 yr)	[9]
C	64	Female	2	Ulcerative (both 2 lesions)	(-)	(-)	PD (both lesions)	R-CHOP × 3 courses + gastric irradiation	Maintaining CR (≥ 6 yr)	[9]

MALT: Mucosa-associated lymphoid tissue; MGUS: Monoclonal gammopathy of undetermined significance; CR: Complete remission; SD: Stable disease; PD: Progressive disease; RTX: Rituximab; R-CHOP: Rituximab + cyclophosphamide, doxorubicin, vincristine and prednisone; R-THP-COP: Rituximab + cyclophosphamide, pirarubicin, vincristine and prednisone; IgG: Immunoglobulin G.